Despite being slightly different in their T cell subset requirement, with CD4+ (128) versus CD8+ T cells (130) being more important for primary tumor clearance following anti-CD20 mAb therapy, the mechanisms involved in the various models are not necessarily mutually exclusive. The gene discussed is CD8A; the disease is neoplasm.